Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes

Diabetes

Volumn 56, Issue 3, 2007, Pages 647-655

  Figarola, James L ^a   Shanmugam, Narkunaraja ^a   Natarajan, Rama ^a   Rahbar, Samuel ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LR 90; METHYLENE BIS[4,4 (2 CHLOROPHENYLUREIDO PHENOXYISOBUTYRIC ACID)]; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN S100B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CELL ADHESION; CELL VIABILITY; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; MONOCYTE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; UMBILICAL VEIN;

ANTIGENS, NEOPLASM; BUTYRATES; CELL ADHESION; CELL LINE; CELL SURVIVAL; ENZYME ACTIVATION; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; MEMBRANE GLYCOPROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; NADPH OXIDASE; NERVE GROWTH FACTORS; NF-KAPPA B; OXIDATIVE STRESS; S100 PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33847344765     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-0936     Document Type: Article

References (49)

1. Singh R, Barden A, Mori T: Beilin: Advanced glycation end-products: a review. Diabetologia 44:129-146, 2001
2. DeGroot J: The AGE of the matrix: chemistry, consequence and cure. Curr Opin Pharmacol 4:301-305, 2004
3. Basta G, Schmidt AM, De Caterina R: Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63:582-592,2004
4. Renard C, Van Obberghen E: Role of diabetes in atherosclerotic pathogenesis: what have we learned from animal models? Diabete Metab 32:15-29, 2006
5. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570-2581, 2002
6. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143:1699-712, 1993
7. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP: Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:876-886, 2005
8. Soulis T, Thallas V, Youssef S, Gilbert RE, McWilliam BG, Murray-McIntosh RP, Cooper ME: Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40:619-628, 1997
9. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD: Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000 11:1656 -1666, 2000
10. Schmidt AM, Yan SD, Yan SF, Stern DM: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys 1498:99-111, 2000
11. Kim W, Hudson BI, Moser B, Guo J, Rong LL, Lu Y, Qu W, Lalla E, Lerner S, Chen Y, Yan SS, D'Agati V, Naka Y, Ramasamy R, Herold K, Yan SF, Schmidt AM: Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis. Ann N Y Acad Sci 1043:553-561, 2005
12. Wendt T, Bucciarelli L, Qu W, Lu Y, Yan SF, Stern DM, Schmidt AM: Receptor for advanced glycation endproducts (RAGE) and vascular in-flammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 4:228-237, 2002
13. Naka Y, Bucciarelli LG, Wendt T, Lee LK, Rong LL, Ramasamy R, Yan SF, Schmidt AM: RAGE axis: animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol 24:1342-1349, 2004
14. Nawroth P, Bierhaus A, Marrero M, Yamamoto H, Stern DM: Atherosclerosis and restenosis: is there a role for RAGE? Curr Diab Rep 5:11-16, 2005
15. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 4:1025-1031, 1998
16. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106:2827-2835, 2001
17. Marx N, Walcher D, Ivanova N, Rautzenberg K, Jung A, Friedl R, Hombach V, de Caterina R, Basta G, Wautier MP, Wautiers JL: Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 53:2662-2668, 2004
18. Yamagishi S, Takeuchi M: Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs Exp Clin Res 30:169-175, 2004
19. Hudson BI, Bucciarelli LG, Wendt T, Sakaguchi T, Lalla E, Qu W, Lu Y, Lee L, Stern DM, Naka Y, Ramasamy R, Yan SD, Yan SF, D'Agati V, Schmidt AM: Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys 419:80-88, 2003
20. Rahbar S, Figarola JL: Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 419:63-79, 2003
21. Figarola JL, Scott S, Loera S, Tessler C, Chu P, Weiss L, Hardy J, Rahbar S: LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 46:1140-1152
22. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL: Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685-E694, 2001
23. Sumimoto H, Ueno N, Yamasaki T, Taura M, Takeya R: Molecular mechanism underlying activation of superoxide-producing NADPH oxidases: roles for their regulatory proteins. Jpn J Infect Dis 57:S24-S25, 2004
24. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM: NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 8:691-728, 2006
25. Hayden MS, Ghosh S: Signaling to NF-kappaB. Genes Dev 18:2195-2224, 2004
26. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, Gerritsen ME: Novel inhibitors of cytokine-induced IκB-α phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 272:21096 -21103, 1997
27. Osterud B, Bjorklid E: Role of monocytes in atherogenesis. Physiol Rev 83:1069-112, 2003
28. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126, 1999
29. Libby P: Inflammation in atherosclerosis. Nature 42:868-874, 2002
30. Gerrity RG: The role of the monocyte in atherogenesis. I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 103:181-190, 1981
31. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D: Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 91:2155-2168, 1993
32. Shanmugam N, Reddy MA, Guha M, Natarajan R: High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 52:1256-1264, 2003
33. Shanmugam N, Kim YS, Lanting L, Natarajan R: Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J Biol Chem 278:34834-34844, 2003
34. Shanmugam N, Ransohoff RM, Natarajan R: Interferon-{gamma}-inducible protein (IP)-10 mRNA stabilized by RNA-binding proteins in monocytes treated with S100b. J Biol Chem 281:31212-31221, 2006
35. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889-989, 1994
36. Cathcart MK: Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscler Thromb Vasc Biol 24:23-28, 2004
37. - generation by mononuclear phagocytes in diabetes. J Leokocyte Biology 81:2007 (E-pub ahead of print)
38. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling KK: Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105:1429-1435, 2002
39. Wassman S, Wassmann K, Nickenig G: Modulation of oxidant and antioxidant expression and function in vascular cells. Hypertension 44:381-386, 2004
40. phox. J Biol Chem 281:5657-5667, 2006
41. de Winther MP, Kanters E, Kraal G, Hofker MH: Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 25:904-914, 2005
42. Gilmore TD: Rel/NF-kappaB transcription factors [article online]. Available from http://people.bu.edu/gilmore/nf-kb/. Accessed 3 July 2006
43. Li N, Karin M: Is NF-kappaB the sensor of oxidative stress? FASEB J 13:1137-1143, 1999
44. Xiong S, She H, Takeuchi H, Han B, Engelhardt JF, Barton CH, Zandi E, Giulivi C, Tsukamoto H: Signaling role of intracellular iron in NF-kappaB activation. J Biol Chem 278:17646-17654, 2003
45. Rollins BJ: Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today 2:198-204, 1996
46. Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, Harada A, Matsushima K, Kelvin DJ, Oppenheim JJ: Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 177:1809-1814, 1993
47. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner KT, Nawroth PP: The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 198:1507-1515, 2003
48. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395-1403, 1995
49. Botella LM, Puig-Kroger A, Almendro N, Sanchez-Elsner T, Munoz E, Corbi A, Bernabeu C: Identification of a functional NF-kappa B site in the platelet endothelial cell adhesion molecule-1 promoter. J Immunol 164:1372-1378, 2000